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ABSTRACT
Objective To analyse how non-adherence to prescribed
treatments might be prevented, screened, assessed and
managed in people with rheumatic and musculoskeletal
diseases (RMDs).
Methods An overview of systematic reviews (SR) was
performed in four bibliographic databases. Research
questions focused on: (1) effective interventions or
strategies, (2) associated factors, (3) impact of shared
decision making and effective communication, (4) practical
things to prevent non-adherence, (5) effect of non-
adherence on outcome, (6) screening and assessment tools
and (7) responsible healthcare providers. The
methodological quality of the reviews was assessed using
AMSTAR-2. The qualitative synthesis focused on results and
on the level of evidence attained from the studies included in
the reviews.
Results After reviewing 9908 titles, the overview included
38 SR on medication, 29 on non-pharmacological
interventions and 28 on assessment. Content and quality of
the included SR was very heterogeneous. The number of
factors that may influence adherence exceed 700. Among
53 intervention studies, 54.7% showed a small statistically
significant effect on adherence, and all three
multicomponent interventions, including different modes of
patient education and delivered by a variety of healthcare
providers, showed a positive result in adherence to
medication. No single assessment provided
a comprehensive measure of adherence to either
medication or exercise.
Conclusions The results underscore the complexity of
non-adherence, its changing pattern and dependence on
multi-level factors, the need to involve all stakeholders in all
steps, the absence of a gold standard for screening and the
requirement of multi-component interventions to manage it.
INTRODUCTION
Thirty per cent to eighty per cent of people
with rheumatic and musculoskeletal diseases
(RMDs) do not follow the prescribed treat-
ment plan. This non-adherent behaviour has
a negative impact on pharmacological and/or
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Key messages
What is already known about this subject?
► Non-adherent behaviour is common among people
with chronic diseases; for example, 30–80% of
people with rheumatoid arthritis do not adhere to
treatment at some point of their disease, potentially
leading to more disease activity, unnecessary
treatment adaptations, loss of quality of life and
increased healthcare costs.
What does this study add?
► Non-adherence is triggered by multiple
determinants, many of which are not modifiable,
and none of which stands as a sole predictor of
possible non-adherent behaviour.
► Non-adherence can be assessed by multiple
instruments; however, no gold standard exists.
► Social factors, healthcare-related factors, disease
characteristics, as well as therapy-related factors play
a potentially important role in adherence; consequently,
multicomponent interventions have proven to be the
most effective response to non-adherent behaviours.
How might this impact on clinical practice?
► This systematic review has formed the basis of 2020
EULAR points to consider how to facilitate adherence
in people with RMDs.
Epidemiology
Ritschl V, et al. RMD Open 2020;6:e001432. doi:10.1136/rmdopen-2020-001432 1
 on January 14, 2021 by guest. P
rotected by copyright.
http://rm
dopen.bm
j.com
/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2020-001432 on 7 N
ovem
ber 2020. D
ow
nloaded from
 
non-pharmacological interventions and keeping appoint-
ments of follow-up visits.1–5 Moreover, being non-
adherent is associated with worse clinical outcomes,
such as increased risk of cardiovascular disease, decreased
functioning and loss of health-related quality of life.2–7
Strategies to prevent and/or manage non-adherence are
thus essential to achieve an optimal disease outcome.4 6 7
Many EULAR recommendations for the management of
specific RMDs highlight the importance of adherence to
achieve the desired effect of interventions.8–11 However,
these recommendations do not orient healthcare provi-
ders on how to work collaboratively with the patients to
support them to adhere to their treatment plans.
A EULAR taskforce was formed to focus on non-
adherence across RMDs. Non-adherence affects most
types of RMDs and interventions; moreover, it is
a complex behaviour that concerns all healthcare pro-
viders in rheumatology. An example of the complexity
is the influence of a social context. Therefore, success-
ful interventions depend not only on the capability
and motivation of the individual patient, but also on
contextual factors such as the capability and motiva-
tion of, for instance, a spouse or a caregiver.12 To
facilitate a multidisciplinary, multifaceted approach
to support adherent behaviour in people with RMDs,
taking all these factors into account, the taskforce set
out to identify and critically appraise evidence for
preventing, screening, assessing and managing non-
adherence.
METHODS
We performed a systematic review of systematic reviews
(SR) following the guidelines of the Cochrane
Collaboration,13 and reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement.14 According to the
EULAR Standard Operating Procedures,15 an interna-
tional expert task force was formed, including people
with RMDs and representatives from relevant healthcare-
provider groups: nurses, occupational therapists, psychol-
ogists, physiotherapists, pharmacists and rheumatolo-
gists. The task force developed and formulated the
following clinical questions with the aim of covering the
entire therapeutic process: (1) What strategies are effica-
cious in facilitating adherent behaviour? (2) What are the
factors (barriers, facilitators and so on) that need to be
considered to minimise or reduce non-adherence? (3)
What is the impact of shared decision making (SDM)
and of effective communication on non-adherence? (4)
What are the practical things we can do in order to pre-
vent non-adherence? (5) What are the effects of non-
adherence on outcome? (6) How is non-adherence
screened/detected? (7) Which healthcare providers are
responsible for facilitating adherent behaviour? All these
questions were translated into their corresponding PICO
(Population; Intervention/factor; Comparator; Out-
come; in addition, the type of study) formulae (table 1).
Search strategy
We conducted an electronic search of the following
databases: Medline (via PubMed), Embase, CINAHL
and Cochrane databases, from inception until
12 June 2018. Due to the broad spectrum of the
topic, the task force decided to limit the search to
the most important/frequent topics, being ‘drug ther-
apy’, ‘exercise’, ‘nutrition’ and ‘visits’. We used com-
prehensive free text and MeSH synonyms for
‘adherence to drug therapy’, ‘adherence to exercise’,
‘adherence to diet’ and ‘adherence to visits’, plus
synonyms of RMDs, with a filter for SR. ‘Exercise’ in
this context refers to any physical activity, exercise or
training; ‘visits’ mean regular medical check-ups with
a healthcare provider. Additionally, a search strategy
was developed to capture studies of instruments to
assess adherence in RMDs. The electronic search stra-
tegies are available as a supplemental file (online sup
plemental A). We limited the search to reviews in
adults and articles published in English during the
last 10 years. It was decided by the task force to
exclude children and adolescents (below the age of
18) from the literature search, as their non-adherent
behaviour differs from that of adults, mainly on its
great reliance on social support of caregivers.12
Study selection
The selection criteria of the studies were different for
each of the questions and based on their specific PICO
(table 1). Two authors (JBN, AdT) independently
assessed the electronic search results for each of the
questions. They first screened studies by title and then
by abstract. When an article title seemed relevant, the
abstract was reviewed for eligibility. If there was any
doubt, the full text of the article was retrieved and
appraised for possible inclusion. Any differences among
the two authors were discussed, and if necessary, a third
author (LC) was referred to for arbitration. A reason for
exclusion was recorded in all cases if the article was not
eligible or excluded (online supplementals B–H).
Risk of bias assessment
Cochrane SR were included without further critical
appraisal, as it is mandatory for them to follow rigorous
methods.13 Any other SR underwent a critical appraisal by
one author (VR), supervised by themethodologist (AdT),
using the AMSTAR 2 tool.16 The quality and risk of bias of
the original studies were obtained directly from the pub-
lished SR.
Data extraction and synthesis
Three authors (VR, LC and JBN) extracted the data,
supervised by the methodologist (AdT). Data included
design, population, intervention or factors studied, com-
parator (if applicable), outcome(s)measured and results.
The results were synthesised qualitatively for each clin-
ical question. No meta-analysis was intended, as the het-
erogeneity across studies in terms of population,
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interventions and outcomes measured precluded such
quantitative approach.
RESULTS
The search strategies yielded 9908 records, of which 3600
were related to adherence to medication, 2357 to exer-
cise, 542 to diet, 1872 to visits and 1537 to the screening or
assessment of adherence in RMD. After exclusion of
duplicates and title/abstract screening, 95 studies were
analysed in full text. According to the different inclusion
and exclusion criteria, a different number of papers was
included for each PICO. The PRISMA flowchart of the
study selection is depicted in figure 1.
Risk of bias of the included SR
The quality of the SR was in general low. The quality of
the included individual studies is described for each clin-
ical question (online supplementals B–H).
Population of the included studies
There are more than 200 RMDs;17 however, the studies
found in the reviews dealing with non-adherence and
RMDs contained only eight different RMDs: rheumatoid
arthritis (RA), osteoporosis, systemic lupus erythemato-
sus (SLE), osteoarthritis (OA), gout, spondyloarthritis,
psoriatic arthritis and low back pain.
Clinical question 1: what strategies are efficacious in
facilitating adherent behaviour?
We included studies examining interventions aiming at
improving non-adherent behaviour in comparison to
standard care or other interventions. We searched for
articles regarding medication/exercise adherence,
adherence to diet/visits (See full report in online supple
mental_B_PICO_1).
The screening by title and abstract yielded 38 studies to
be appraised in full-text, of which four were SR on inter-
ventions to improve adherence tomedication,15 18–20 eight
SR on adherence to exercise21–28 and one on adherence to
scheduled visits.29 We did not find any reviews regarding
adherence to diet specifically in RMDs. In total, these
reviews included 17 original studies on adherence to
medication,30–46 33 on exercise or physical activity33 47–79
and three on visits.80–82
Due to the variety of interventions, we classified
them into six categories: (1) educational (enhance
patient knowledge), (2) behavioural (providing incen-
tives for medication taking), (3) cognitive behavioural
(altering thinking patterns) and (4) multicomponent
intervention (multiple strategies used).18 83 For exer-
cise, two categories were added: (5) motivational
(increasing motivation) and (6) supervised/class-
based exercises. Interventions that did not fit into
these categories were classified as ‘others’, such as
Table 1 The clinical questions/PICOs addressed in this review. Questions #1 to #5 and #7 were answered on the basis of the
articles identified in the first literature search. An additional literature search was performed to answer question #6 (online
supplemental A)
# Clinical question P I C O
1 What strategies are efficacious in
facilitating adherent behaviour?
Adults
with
any
RMD
Any intervention or
strategy managing
non-adherence
SoC or
other
strategy
Adherence
2 What are the factors (barriers,
facilitators) that need to be considered
to minimise or reduce non-adherence?
– – Barriers and facilitators of adherence
3 What is the impact of SDM and of
effective communication on non-
adherence?
SDM and effective
communication
– Adherence
4 What are the practical things we can do
in order to prevent non-adherence?
Effective interventions
or strategies for
enhancing adherence
– Components of intervention
5 What are the effects of non-adherence
on outcome?
(Non-)Adherence – Outcome:
Treatment effect, Function
Disability
Structural damage
Fracture
6 How is non-adherence screened/
detected?
Measurement or
screening instruments
– Screening performance
Metric properties
7 Which healthcare providers are
responsible for managing non-
adherence?
Effective interventions
or strategies for
enhancing adherence
– Health-care provider performing
intervention
PICO, Population; Intervention/factor; Comparator; Outcome; RMD, rheumatic and musculoskeletal disease; SoC, standard of care; SDM,
shared decision making.
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computer-assisted video instructions (to conventional
education)77 or cost-free programmes compared to
fee-based-programmes.76
The results were very heterogeneous in terms of
diagnosis, interventions, outcome measures (see clin-
ical question 6) and in regard of effectiveness. More
than half of all interventions (n=29, 54.7%) included
an educational or behavioural approach. Among the
53 studies included in the SR, 29 (54.7%) documen-
ted a small statistically significant effect on adherence.
Among the remaining studies, six documented an
unclear effect, and in 18 studies, no statistical signifi-
cance was reached. All three multicomponent inter-
ventions showed a positive result in adherence to
medication. Studies using cognitive behavioural or
motivational approaches showed positive results;
however, only three such studies were included in
the SR (table 2).
Clinical question 2: what are the factors (barriers, facilitators)
that need to be considered to minimise or reduce non-
adherence?
We included SR, specifically aiming at describing barriers
or facilitators of adherence to medication or to exercise
or physical activity (See full report in online supplemen
tal_C_PICO_2). After excluding narrative reviews, expert
opinions and reviews on interventions, 15 SR on factors
affecting medication non-adherence84–98 and four on
exercise99–102 were included.
Determinants for medication non-adherence are multi-
faceted.84–98 Some factors may change over time and can
act both as a cause and as a consequence of non-
adherence. For example, clinical improvement seems to
increase non-adherence behaviour. This may lead to wor-
sening of symptoms which may urge patients to become
more adherent.90
Some factors are not modifiable, for example, age and
gender, and none is considered an isolated predictor of
non-adherence.84 87 88 In their SR, Kardas & Lewek iden-
tified 771 individual factors related to medication non-
adherence, covering 19 different diseases.90 They
grouped their results into 40 clusters, mapped into the
five WHO categories: socio-economic factors, healthcare
team and system-related factors, condition-related fac-
tors, therapy-related factors, patient-related factors.103
Only four reviews addressed factors related to adher-
ence to exercise.99–102 Similar to adherence to medica-
tion, adherence to exercise or physical activity is affected
by multiple determinants. A SR, including low risk of bias
studies, demonstrated that knowledge, skills, social or
professional identity, beliefs about capabilities, optimism,
beliefs about consequences and reinforcement influence
adherence behaviour to exercise among patients with hip
or knee OA.99 The Cochrane mixed methods review by
Hurley & Dickson concluded that (1) better information
and advice about the safety and value of exercise, (2)
exercise tailored to individuals’ preferences, abilities
and needs and (3) verbalisation of inappropriate health
beliefs and better support, reduced non-adherent beha-
viour to exercise.100
Clinical question 3: what is the impact of shared decision
making (SDM) and of effective communication on non-
adherence?
To answer clinical question 3, all interventions included
in the SR for PICO 1 were reviewed in detail, specifically
seeking components of effective communication or SDM.
Although no evidence was found specifically on the
impact of SDM or effective communication on non-
adherence in RMDs (See full report in online supplemen
tal_D_PICO_3), the results to the next clinical question
were very much related.
Figure 1 PRISMA flow diagram. This flow chart shows the
study selection for the search strategies and PICOs. As the
PICOs had different exclusion and inclusion criteria, the
number of excluded and included articles varies. PRISMA,
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses; PICO, Population; Intervention/factor;
Comparator; Outcome.
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Clinical question 4: what are the practical things we can do in
order to prevent non-adherence?
To better guide HCP in clinical routine, to better
support patients in their adherence, we searched stu-
dies for useful and effective ‘everyday’ ideas and sug-
gestions. All interventions proven effective in the SR
of PICO 1 were reviewed in detail. The individual
components of the effective interventions were col-
lected and summarised (See full report in online sup
plement_E_PICO_4).
One important practical aspect was patient education
(PE), defined, according to the EULAR recommenda-
tions, as a ‘planned interactive learning process designed
to support and enable people to manage their life with
inflammatory arthritis and optimise their health and well-
being’.10 Five SR including 51 studies explored the asso-
ciation between (different) modes of PE and adherence
in people with RMDs. Fifteen studies had a positive
impact on non-adherence, nine of which were studies
on medication,30 31 36 37 39–42 104 and six on exercise.50
52 66 70 79 105 Nine studies showed a positive, but not
statistically significant effect; five studies on
medication,32 43 45 105 106 and four on exercise.53 55 61 75
The PE modes to enhance adherence to medication var-
ied greatly: daily text messages to provide reminders and
education,41 information and writtenmaterials,31 42 chart
visualisation of disease progression,37 discussion of
patient-reported outcome measures (=PROMs),42 coun-
selling and advice,45 motivational interview.43 106 The PE
interventions for adherence to exercise also were varied:
consultations,52 55 75 105 motivational approaches,70 phy-
sical activity advice50 and verbal (recorded tapes) and
visualised (videos) cues to prompt correct performance
of exercise.53 Regarding the content of the PE to improve
medication adherence, this included information about
drugs,31 36 disease process,31 36 physical exercise,31 joint
protection,31 42 pain control,31 42 coping strategies31 and
lifestyle changes.36 42 The studies which focused on PE to
improve adherence to exercise include additional infor-
mation about physical exercise, endurance activities
(walking, swimming, bicycling), advice on energy conser-
vation and joint protection.105 Themode of delivering PE
was diverse: verbally, either by face to face,31 or by
telephone,30 written, as in leaflets,31 or in text
messages,39 41 and visualised, as in charts.37
In addition to PE, other practical things to prevent
non-adherence were mentioned in the studies. Patients
should be given the ability to express questions and
doubts.36 Physicians and health professionals in rheu-
matology (HPRs) should review the plans and strategies
and provide feedback and solve any doubts.104 Adher-
ence behaviour is supported by interventions that are
individualised or tailored according to predefined goals
and preferences of the patient.40 50 66 Effective interven-
tions included the encouragement of patients to set
realistic goals in planning their treatment regimens,
and the training of patients in proper execution of phy-
sical exercises.105 They also included photos displaying
exercises and explanatory written information,79 and
discussed issues of non-adherence, possible alternatives
and solutions with the patient105 (table 3). Following the
perceptions of healthcare providers, organisational
aspects, such as limited consultation time, were the
main obstacles to effective communication.52 Social
support58 60 62 63 67 68 was used to support adherence
to physical activity and exercises. Reminders did not
increase the use of hydroxychloroquine but to follow
up visits.39
Table 2 Summary of the included studies, PICO 1
Dx Edu Beh CBT Mot Sup MCo Oth
Medication RA 3+/3− 1+/1− 1+ 2+ 1~
SLE 1+ 1−
Psoriasis 1+
OP 1~/1−
Total 4+/3− 1+/2− 1+ 3+ 2~/1−
Exercise OA 2+/4− 3− 1+ 2+/1− 3+/2−
RA 2+ 3+/2− 3~
Mixed 1+ 1+
CBP 1~ 1+ 1+
Total 5+/4− 4+/1~/5− 2+ 2+/1− 1+/3~ 3+/2−
Visits RA 3+
SLE
Total 3+
Beh, behavioural interventions; CBP, chronic back pain; CBT, cognitive–behavioural therapy; Dx, diagnosis; Edu, educational interventions;
MCo, multicomponent interventions; Mot, motivational interventions; OA, osteoarthritis; OP, osteoporosis; Oth, other interventions; PICO,
Population; Intervention/factor; Comparator; Outcome; RA, rheumatoid arthritis; Sup, supervised exercise; SLE, systemic lupus erythematosus.
The numbers indicate the count of the studies. Numbers followed with a ‘+’ indicate significant increase in adherent behaviour, ‘−’ means no
increase in adherent behaviour and ‘~’ means unclear results.
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Clinical question 5: what are the effects of non-adherence on
outcome?
To answer clinical question 5, all individual studies
included in the first SR were reviewed. Studies were
included if, besides adherence, other clinical out-
comes, such as disease activity or patient’s perspec-
tive, were measured and the association with
adherence analysed (See full report in online supple
mental_F_PICO_5).
None of the included studies specifically focused or
analysed the impact of non-adherent behaviour on health
outcomes. However, in some studies, differences in clin-
ical outcomes were seen between groups of patients with
high adherence scores compared with less adherent
patients. The association was evident in terms of improve-
ment in disease severity,37 39 41 42 pain,37 41 42 79 functional
status,37 40–42 70 79 fatigue,40 depression40, quality of life37
41 42 70 and physical activity levels.50 52 66 105
Clinical question 6: how is non-adherence screened/detected?
For this question, the type of studies targeted were valida-
tion studies of questions, questionnaires, tailored assess-
ments and other kinds of measures to assess and/or
screen non-adherence in people with RMDs (See full
report in online supplemental_G_PICO_6). While con-
ducting our review, a SR of tools to assess adherence to
medication, which passed our AMSTAR2 quality check,
was presented at the Eular Congress.107 It included 242
validation studies, and identified four questionnaires
(patient-reported outcome measures) that have been
used to measure non-adherence to medication in inflam-
matory arthritis: the Compliance Questionnaire in Rheu-
matology (CQR),108 the Medication Adherence Report
Scale (MARS),109 the Morisky Medication Adherence
Scale (MMAS)110 111 and the Medication Adherence Self-
report Inventory (MASRI).112 The most commonly used
measurement is the MMAS, although it is subject to a fee
Table 3 Summary of practical things we can do in order to prevent non-adherence
Medication adherence
Practical thing we can do Examples/descriptions
Education/information should include information
about
► Drugs
► Disease process
► Physical exercise
► Joint protection
► Pain control
► Coping strategies
► Lifestyle changes
Education/information can be delivered ► Verbally (face to face or by telephone)
► Written (leaflets or text messages)
► Visualised in charts
Cueing For example: pairing medication taking with an established behaviour such
as brushing teeth
Monitoring For example: using a calendar to track medication taking
Positive reinforcement For example: praising and rewarding with tokens that are exchanged for
special privileges
Possibility to express questions and doubts Patients should have the possibility to express questions and doubts
Review of plans/strategies Physician and other health professionals should review the plans/strategies
and give feedback/answers
Individualised/tailored treatment Individualised/tailored treatment according to patient preferences and goals
Exercise adherence
Practical thing we can do Examples/descriptions
More consults/time Overcome the constraint of consultation time
Use psychosocial factors relevant for the
motivational approach as proxy efficacy
Proxy efficacy refers to patients’ confidence in their therapists’ ability to
function effectively on their behalf
Education/information should include information
about
► Physical exercises
► Endurance activities (walking, swimming, bicycling)
► Advice on energy conservation
► Joint protection
Discuss problems Discuss problems regarding exercise adherence and offer solutions
Encourage patients to take responsibility For example: to plan their treatment regimens, discuss intentions and help
recasting unrealistic plans
Individualised/tailored treatment Individualised physical activity advice and tailored graded exercise
programme according to the preferences and goals of the patient.
Train in proper execution of physical exercises Photos displaying these exercises and explanatory written information
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and not fully validated in rheumatology. The CQR and
MASRI questionnaires are the most widely validated in
rheumatology; however, the CQR is an 18-item question-
naire, and hence, most suitable for research purposes.
Within rheumatology, the MASRI has only been used in
SLE.113 The authors of the SR concluded that up to date,
a simple, reliable and valid questionnaire to assess medi-
cation adherence in daily clinical practice is not available.
We then focused our SR on measurements of adher-
ence to exercise. Three SR covering 162 individual stu-
dies and describing 76 ways of measuring non-adherence
to prescribed exercise interventions were
identified.114–116 Currently, there is no gold standard
measurement of adherence to exercise. The existing
ones can be categorised as (1) (self-developed) question-
naires, scales, interviews or surveys (eg, asking for exer-
cise-frequencies)117; (2) diaries or logbooks (eg,
counting frequencies)118 and (3) other type of assess-
ments (eg, different types of monitors and devices, such
as StepWatch ActivityMonitor (SAM)).115 Themajority of
tools do not have a proper description or testing of their
metric properties available, except for the Heart Failure
ComplianceQuestionnaire,119 the Adherence to Exercise
Scale for Older Patients (AESOP)120 and The Proble-
matic Experiences of Therapy Scale121; however, none
of these scales are specifically developed or tested
among people with inflammatory arthritis.
Clinical question 7: which healthcare providers are responsible
for managing non-adherence?
To answer clinical question 7, all interventions in the
included SR that showed a positive effect were reviewed
in detail (See full report in online supplemental_H_
PICO_7). The healthcare providers delivering these
effective interventions were ranked by frequency, rheu-
matologists or other physicians,37 42 52 79 105 nurses,31 104
pharmacists,30 36 physiotherapists,66 70 therapists,40 exer-
cise physiologist50 and patient educators.43
DISCUSSION
This overview of SR allowed us to answer clinical ques-
tions regarding adherence in RMDs. Despite the lack of
assessment standards and evidence for interventions,
non-adherence is a behaviour that is assumed to lead to
a worse outcome and should therefore be addressed.
The findings of these reviews informed a EULAR task
force developing the 2020 EULAR points to consider for
the prevention, screening, assessment and management
of non-adherence in people with RMDs. The intention to
use this type of review compared to others was to examine
only the highest level of evidence. A strength of this type
of review is that it provides an overall picture of findings.
Therefore, a SR of SR is an ideal means to provide rapid
evidence synthesis for clinical decision-makers with the
evidence they need.122 123 A challenge in doing such
overview is the risk of including data from individual
studies more than once. This could happen if studies
are included in two or more reviews. This would result
in amisleading estimate.122 123 To overcome this obstacle,
once we selected the reviews we analysed the results of the
individual studies, including them only once.
The PICOs/clinical questions formulated in the first
task-force meeting aimed to cover the entire therapeutic
process. The questions focused on prevention, screening,
assessment andmanagement of non-adherent behaviour.
We only included adults who are independent of care-
givers. We believe that the inclusion of caregivers requires
a comprehensive extension of the scope and search. Chil-
dren and older people or people with cognitive limitation
who are dependent on a guardian/carer need special
attention in terms of non-adherence.12 For this group of
people, non-adherence behaviour differs from that of
adults, mainly due to the great reliance on social support
of caregivers.12
Our main message from this review is that adherence is
very complex in nature, and thus that there is no single
explanation for non-adherence. This means, there is no
single factor for being non-adherent, but multiple factors
influencing each other. Nevertheless, most studies have
not considered the individual factors leading to non-
adherence, and consequently used one and the same
approach for all patients. This might be one of the rea-
sons why especially tailored multi-component strategies
are more efficacious compared to single interventions.
However, to be evaluated, these tailored multi-
component strategies require complex methods, very
large sample sizes to avoid noise and solid outcome mea-
sures, which do not seem to be available.
We did not find any review that examined the impact of
SDM or effective communication on (non-)adherence.
Furthermore, we did not find a clear definition of ‘effec-
tive communication’ in healthcare. Instead of ‘effective
communication’ we found ‘patient education/informa-
tion’ to be similar to the term ‘effective communication’
(as it was understood from the task force) and an impor-
tant tool to support patients in their adherent behaviour.
With regard to SDM, we found that patient-tailored
approaches are more effective than non-tailored
approaches. However, since the results did not answer
question 3, we moved these findings to question 4.
In accordance to the very complex nature of non-
adherence, there is no gold-standard for screening or
assessing it. Moreover, when adherence is discussed
directly by a healthcare provider, there will be a risk of
socially desirable answers. Healthcare providers have to
take this into account, when they are evaluating (non-)
adherence to a treatment regimen.
We acknowledge that our review has certain limitations.
Most of the SR and studies included focused only on
osteoarthritis, gout, osteoporosis and RA. Other types of
inflammatory arthritis are under-represented and this
may have introduced a bias of the results. Most of the SR
and studies had adherence to medication or exercise as
outcome. Adherence to diet and clinical visits was under-
represented in this review. Further, the data extraction
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was performed by only one researcher. A disadvantage of
using a review of reviews is that there may be studies in
recent years, which were not included in any review, and
therefore are not included in this overview as well. In
addition, SR of SR should not only summarise the evi-
dence, but should also include a resynthesis of the
data.122 123 Due to the high heterogeneity, we were not
able to perform a meta-analysis across the different
reviews. We have focused solely on the effectiveness of
interventions to support adherent behaviour in people
with RMDs. Feasibility, cost-effectiveness and other fac-
tors were not further considered. Healthcare providers
have to take in mind that the results of this review are
based on study context, which can be different to daily
practice. Finally, all studies suffered from somemethodo-
logical limitations that impacted the level of evidence.
In conclusion, the results underscore the complexity of
non-adherence, its changing pattern and dependence on
multi-level factors. As agreement is part of the definition
of adherence in the sense, that people with RMDs have to
agree to the treatment plan, the need to involve all stake-
holders, meaning healthcare providers and people with
RMDs in all phases of treatment (prevention, screening,
assessment and management), became obvious. The
absence of a gold standard for screening and assessing
non-adherence, and the requirement of multi-
component interventions to manage it, sets an agenda
for future research.
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